4D Molecular Therapeutics' Losses Widen Amid R&D Surge

TL;DR

**FDMT's cash burn is accelerating with R&D, making it a high-risk bet on pipeline success.**

AI Summary

4D Molecular Therapeutics, Inc. reported a net loss of $62.1 million for the three months ended June 30, 2025, an increase from a net loss of $50.3 million for the same period in 2024. For the six months ended June 30, 2025, the net loss was $120.9 million, up from $98.1 million in the prior year. Revenue from collaboration and license agreements decreased significantly to $0.5 million for the three months ended June 30, 2025, compared to $1.5 million in the prior year, primarily due to the Cystic Fibrosis Foundation agreement. Research and development expenses increased to $53.9 million for the three months ended June 30, 2025, from $44.0 million in 2024, driven by increased clinical trial activities and personnel costs, despite a workforce reduction charge of $2.0 million. General and administrative expenses also rose to $10.0 million from $8.0 million. The company completed a follow-on public offering in February 2024, raising approximately $200.0 million in net proceeds, and has an At-The-Market (ATM) offering program with Jefferies LLC for up to $150.0 million. The strategic outlook focuses on advancing its gene therapy pipeline, including 4D-710 for cystic fibrosis and 4D-150 for wet AMD, but faces substantial capital requirements and clinical development risks.

Why It Matters

This widening net loss and increased R&D spend signal a critical juncture for 4D Molecular Therapeutics. For investors, continued losses without significant clinical milestones could erode shareholder value, especially given the reliance on public offerings and ATM programs for funding. Employees face potential future workforce adjustments if clinical trials falter or funding becomes constrained. Customers, particularly patients awaiting gene therapies for conditions like cystic fibrosis and wet AMD, depend on the company's ability to successfully navigate these financial and developmental challenges. In the competitive gene therapy landscape, sustained losses and slow progress could put FDMT at a disadvantage against better-capitalized rivals, impacting its long-term viability and market position.

Risk Assessment

Risk Level: high — The company reported a net loss of $62.1 million for Q2 2025, an increase from $50.3 million in Q2 2024, and a cumulative net loss of $120.9 million for the first six months of 2025. This significant and increasing cash burn, coupled with a decrease in collaboration revenue from $1.5 million to $0.5 million, indicates substantial financial risk and reliance on external financing, such as the $150.0 million ATM offering program, to fund operations.

Analyst Insight

Investors should closely monitor FDMT's clinical trial progress for 4D-710 and 4D-150, as these milestones are crucial for future valuation. Given the high burn rate and reliance on dilutive financing, consider a cautious approach and evaluate the company's cash runway against its projected R&D expenditures.

Financial Highlights

debt To Equity

N/A

revenue

$0.5M

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$62.1M

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

-66.7%

Revenue Breakdown

Key Numbers

• $62.1M — Net Loss (Q2 2025) (Increased from $50.3M in Q2 2024, indicating widening losses.)
• $120.9M — Net Loss (Six Months Ended June 30, 2025) (Increased from $98.1M in the prior year period.)
• $0.5M — Collaboration and License Revenue (Q2 2025) (Decreased from $1.5M in Q2 2024, primarily from Cystic Fibrosis Foundation agreement.)
• $53.9M — Research and Development Expense (Q2 2025) (Increased from $44.0M in Q2 2024, driven by clinical trial activities.)
• $2.0M — Workforce Reduction Charge (Q2 2025) (Included in R&D expenses, reflecting cost-cutting efforts.)
• $200.0M — Net Proceeds from Follow-on Public Offering (Raised in February 2024, providing capital for operations.)
• $150.0M — At-The-Market Offering Program Limit (Potential future capital source through Jefferies LLC.)

Key Players & Entities

• 4D Molecular Therapeutics, Inc. (company) — filer of the 10-Q
• Cystic Fibrosis Foundation (company) — collaboration partner, revenue source decreased
• Jefferies LLC (company) — sales agent for At-The-Market offering program
• UniQure Biopharma B.V. (company) — licensor under UniQure Agreement
• Aevitas Therapeutics, Inc. (company) — licensor under Aevitas Therapeutics Inc. Agreement
• 4D-710 (product) — gene therapy candidate for cystic fibrosis
• 4D-150 (product) — gene therapy candidate for wet AMD

FAQ

Risk Factors

• Increasing Net Losses [high — financial]: The company reported a net loss of $62.1 million for Q2 2025, an increase from $50.3 million in Q2 2024. For the first six months of 2025, the net loss was $120.9 million, up from $98.1 million in the prior year. This widening loss trend indicates substantial ongoing capital requirements for development.
• High R&D Expenses [high — operational]: Research and development expenses increased to $53.9 million in Q2 2025 from $44.0 million in Q2 2024. This rise is attributed to increased clinical trial activities and personnel costs, despite a $2.0 million workforce reduction charge, highlighting the significant investment needed for pipeline advancement.
• Dependence on Capital Raising [high — financial]: The company raised approximately $200.0 million in net proceeds from a follow-on public offering in February 2024 and has an At-The-Market (ATM) offering program for up to $150.0 million. This reliance on external financing underscores the substantial capital needs for gene therapy development and commercialization.
• Clinical Development Risks [high — operational]: The strategic outlook focuses on advancing gene therapy pipeline candidates like 4D-710 for cystic fibrosis and 4D-150 for wet AMD. However, these programs face inherent clinical development risks, including potential trial failures, regulatory hurdles, and efficacy/safety challenges.
• Declining Collaboration Revenue [medium — financial]: Revenue from collaboration and license agreements decreased to $0.5 million in Q2 2025 from $1.5 million in Q2 2024. This significant drop, primarily from the Cystic Fibrosis Foundation agreement, impacts the company's non-dilutive funding sources.
• Increased G&A Expenses [medium — operational]: General and administrative expenses rose to $10.0 million in Q2 2025 from $8.0 million in Q2 2024. While not as substantial as R&D, this increase adds to the overall operating cost structure.

Industry Context

The gene therapy sector is characterized by high R&D intensity, significant capital requirements, and long development timelines. Companies like 4D Molecular Therapeutics operate in a competitive landscape with a focus on addressing unmet medical needs through innovative treatments. Regulatory pathways are complex, and clinical success is paramount for value creation.

Regulatory Implications

As a gene therapy developer, 4D Molecular Therapeutics faces stringent regulatory oversight from bodies like the FDA. Successful navigation of clinical trials, manufacturing standards, and post-market surveillance is critical. Any delays or adverse findings in these areas can significantly impact development timelines and market access.

What Investors Should Do

1. Monitor R&D Spend and Clinical Progress
2. Evaluate Cash Runway and Future Financing Needs
3. Assess Revenue Diversification and Partnership Strategy

Key Dates

• 2025-06-30: End of Q2 2025 reporting period — Period for which financial results and operational updates are reported, showing increased net loss and R&D expenses.
• 2025-08-11: 10-Q Filing Date — Indicates the company has submitted its quarterly report, providing detailed financial and operational information to the public.
• 2024-02-29: Completion of Follow-on Public Offering — Raised approximately $200.0 million in net proceeds, providing crucial capital for ongoing operations and pipeline development.
• 2024-04-01: Start of Q2 2024 reporting period — Comparative period for Q2 2025 results, showing lower net loss and R&D expenses.

Glossary

At-The-Market (ATM) Offering Program

A type of public offering where a company sells shares of its stock over time through an intermediary, typically at prevailing market prices. (Represents a potential future source of capital for 4D Molecular Therapeutics, up to $150.0 million.)

Net Loss

The total expenses of a company exceed its total revenues over a specific period. (4D Molecular Therapeutics reported a net loss of $62.1 million for Q2 2025, indicating ongoing investment and lack of profitability.)

Research and Development (R&D) Expense

Costs incurred by a company in the process of developing new products or services, or improving existing ones. (Increased to $53.9 million in Q2 2025, driven by clinical trial activities, a key expenditure for a biotechnology company.)

Collaboration and License Revenue

Revenue generated from agreements with other companies, often involving licensing of intellectual property or joint development efforts. (Decreased significantly to $0.5 million in Q2 2025, impacting the company's revenue diversification.)

Follow-on Public Offering

An offering of securities by a public company after its initial public offering (IPO). (4D Molecular Therapeutics raised $200.0 million in net proceeds from such an offering in February 2024.)

Workforce Reduction Charge

A one-time expense recognized when a company downsizes its workforce, often due to restructuring or cost-saving measures. (A $2.0 million charge was included in R&D expenses for Q2 2025, indicating efforts to manage costs.)

Year-Over-Year Comparison

Compared to the prior year, 4D Molecular Therapeutics has seen a significant increase in its net losses, with Q2 2025 losses at $62.1 million versus $50.3 million in Q2 2024. Research and development expenses have also climbed substantially to $53.9 million from $44.0 million, reflecting increased clinical trial activities. While collaboration revenue has sharply declined from $1.5 million to $0.5 million, the company has bolstered its financial position through a $200.0 million follow-on offering in February 2024, providing a cushion against the widening operational losses.

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share FDMT The Nasdaq Global Se

Filing Documents

• fdmt-20250630.htm (10-Q) — 3080KB
• fdmt-ex31_1.htm (EX-31.1) — 21KB
• fdmt-ex31_2.htm (EX-31.2) — 21KB
• fdmt-ex32_1.htm (EX-32.1) — 14KB
• 0000950170-25-106244.txt ( ) — 11049KB
• fdmt-20250630.xsd (EX-101.SCH) — 1462KB
• fdmt-20250630_htm.xml (XML) — 1974KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 31 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 41 Item 4.

Controls and Procedures

Controls and Procedures 41 PART II. OTHER INFORMATION 43 Item 1.

Legal Proceedings

Legal Proceedings 43 Item 1A.

Risk Factors

Risk Factors 43 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 111 Item 3. Default Upon Senior Securities 111 Item 4. Mine Safety Disclosures 111 Item 5. Other Information 111 Item 6. Exhibits 112

Signatures

Signatures 113 1 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "aim," "anticipate," "assume," "believe," "contemplate," "continue," "could," "due," "estimate," "expect," "goal," "intend," "may," "objective," "plan," "predict," "potential," "positioned," "seek," "should," "target," "will," "would" and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about: the success, cost and timing of our development activities, preclinical studies and clinical trials, including our clinical trials for 4D-150, 4D-175, 4D-710, 4D-725 and 4D-310; the number, size and design of our planned clinical trials, and what regulatory authorities may require to obtain marketing approval; the timing of Investigational New Drug Application ("IND") enabling studies and results from such studies; the timing and success of lead optimization for our product candidates in lead optimization; the translation of our preclinical results and data into future clinical trials in humans; the timing of any manufacturing runs for materials to be used in patient trials; the timing or likelihood of regulatory filings and approvals; our ability to obtain and maintain regulatory approval of our product candidates, and any related restrictions, limitations and/or warnings in the label of any approved product candidate; our ability to obt

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Condensed Unaudited Financial Statements

Item 1. Condensed Unaudited Financial Statements 4D Molecular Therapeutics, Inc. Condensed Balance Sheets (In thousands, except share and per share amounts) June 30, December 31, 2025 2024 Assets Current assets: Cash and cash equivalents $ 77,159 $ 149,336 Marketable securities 216,066 275,541 Prepaid expenses and other current assets 10,062 10,055 Total current assets 303,287 434,932 Marketable securities, long-term 123,806 80,583 Property and equipment, net 17,505 19,534 Operating lease right-of-use assets, net 19,649 21,074 Other assets 9,390 4,261 Total assets $ 473,637 $ 560,384 Liabilities and Stockholders' Equity Current liabilities Accounts payable $ 8,700 $ 4,386 Accrued and other current liabilities 19,190 18,869 Deferred revenue 1,066 257 Operating lease liabilities, current portion 5,721 5,637 Total current liabilities 34,677 29,149 Deferred revenue, net of current portion 219 1,057 Derivative liability 334 410 Operating lease liabilities, long-term portion 17,356 18,969 Other liabilities 161 193 Total liabilities 52,747 49,778 Commitments and contingencies (Note 8) Stockholders' equity Preferred stock, $ 0.0001 par value, 10,000,000 shares authorized at June 30, 2025 and December 31, 2024; no shares issued and outstanding at June 30, 2025 and December 31, 2024 — — Common stock, $ 0.0001 par value, 300,000,000 shares authorized at June 30, 2025 and December 31, 2024; 46,700,242 and 45,793,942 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively 5 5 Additional paid-in-capital 1,099,373 1,086,567 Accumulated other comprehensive gain 337 229 Accumulated deficit ( 678,825 ) ( 576,195 ) Total stockholders' equity 420,890 510,606 Total liabilities and stockholders' equity $ 473,637 $ 560,384 The accompanying notes are an integral

View Full Filing

View this 10-Q filing on SEC EDGAR